The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Common Infectious Diseases in HIV Infected Persons

HIV 감염인에서 흔히 보는 감염

  • Choi, Jun Yong (Department of Internal Medicine, AIDS Research Institute, Yonsei University College of Medicine)
  • 최준용 (연세대학교 의과대학 내과학교실, 에이즈연구소)
  • Published : 2013.02.01
⟨ Previous Next ⟩

Abstract

Opportunistic infections (OIs) are defined as infections that are more frequent or more severe because of immunosuppression in HIV-infected persons. Before the widespread use of combination antiretroviral therapy (ART), OIs were the major cause of morbidity and mortality of HIV-infected persons. Although hospitalizations and deaths have decreased since the implementation of ART, OIs remain a leading cause of morbidity and mortality in HIV-infected persons. The frequent OIs in HIV-infected persons are tuberculosis, Pneumocystis pneumonia, candidiasis, Cytomegalovirus infection, toxoplasmosis, cryptococcosis, and so on. The aim of the present review is to provide a brief introduction on clinical features, diagnosis and treatment of common OIs in HIV-infected persons.

Keywords

References

  1. Centers for Disease Control (CDC). Pneumocystis pneumonia: Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30: 250-252.
  2. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220: 868-871. https://doi.org/10.1126/science.6189183
  3. Kim JM, Cho GJ, Hong SK, et al. Epidemiology and clinical features of HIV infection/AIDS in Korea. Yonsei Med J 2003;44:363-370. https://doi.org/10.3349/ymj.2003.44.3.363
  4. Oh MD, Park SW, Kim HB, et al. Spectrum of opportunistic infections and malignancies in patients with human immunodeficiency virus infection in South Korea. Clin Infect Dis 1999;29:1524-1528. https://doi.org/10.1086/313516
  5. Choe PG, Park WB, Song JS, et al. Late presentation of HIV disease and its associated factors among newly diagnosed patients before and after abolition of a government policy of mass mandatory screening. J Infect 2011;63:60-65. https://doi.org/10.1016/j.jinf.2011.05.002
  6. Smith DE, McLuckie A, Wyatt J, Gazzard B. Severe exercise hypoxaemia with normal or near normal X-rays: a feature of Pneumocystis carinii infection. Lancet 1988; 2:1049-1051.
  7. Stover DE, Zaman MB, Hajdu SI, Lange M, Gold J, Armstrong D. Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host. Ann Intern Med 1984;101:1-7. https://doi.org/10.7326/0003-4819-101-1-1
  8. Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis 1998;178:1126-1132. https://doi.org/10.1086/515658
  9. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection: NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:693-699. https://doi.org/10.1056/NEJM199503163321101
  10. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS: a double-blind, randomized, trial of oral trimethoprimsulfamethoxazole, dapsone-trimethoprim, and clindamycinprimaquine: ACTG 108 Study Group. Ann Intern Med 1996;124:792-802. https://doi.org/10.7326/0003-4819-124-9-199605010-00003
  11. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993;328:1521-1527. https://doi.org/10.1056/NEJM199305273282103
  12. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: California Collaborative Treatment Group. N Engl J Med 1990;323:1451-1457. https://doi.org/10.1056/NEJM199011223232104
  13. Nakata K, Rom WN, Honda Y, et al. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997; 155:996-1003. https://doi.org/10.1164/ajrccm.155.3.9117038
  14. Ku NS, Oh JO, Shin SY, et al. Effects of tuberculosis on the kinetics of CD4(+) T cell count among HIV-infected patients who initiated antiretroviral therapy early after tuberculosis treatment. AIDS Res Hum Retroviruses 2012 Sep 11 [Epub]. http://dx.doi.org/10.1089/aid.2012.0192.
  15. Batungwanayo J, Taelman H, Dhote R, Bogaerts J, Allen S, Van de Perre P. Pulmonary tuberculosis in Kigali, Rwanda. Impact of human immunodeficiency virus infection on clinical and radiographic presentation. Am Rev Respir Dis 1992;146:53-56. https://doi.org/10.1164/ajrccm/146.1.53
  16. Perlman DC, el-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression: the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA): the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1997;25:242-246. https://doi.org/10.1086/514546
  17. Nahid P, Pai M, Hopewell PC. Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc 2006; 3:103-110. https://doi.org/10.1513/pats.200511-119JH
  18. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-354. https://doi.org/10.7326/0003-4819-146-5-200703060-00006
  19. Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007;44:94-102. https://doi.org/10.1086/510080
  20. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697-706. https://doi.org/10.1056/NEJMoa0905848
  21. Gordin FM, Cohn DL, Sullam PM, Schoenfelder JR, Wynne BA, Horsburgh CR Jr. Early manifestations of disseminated Mycobacterium avium complex disease: a prospective evaluation. J Infect Dis 1997;176:126-132. https://doi.org/10.1086/514014
  22. Havlik JA Jr, Horsburgh CR Jr, Metchock B, Williams PP, Fann SA, Thompson SE 3rd. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis 1992;165:577-580. https://doi.org/10.1093/infdis/165.3.577
  23. Benson CA. Treatment of disseminated disease due to the Mycobacterium avium complex in patients with AIDS. Clin Infect Dis 1994;18(Suppl 3):S237-S242. https://doi.org/10.1093/clinids/18.Supplement_3.S237
  24. Benson CA. Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome. Clin Infect Dis 1994;18(Suppl 3):S218-S222. https://doi.org/10.1093/clinids/18.Supplement_3.S218
  25. Hellyer TJ, Brown IN, Taylor MB, Allen BW, Easmon CS. Gastro-intestinal involvement in Mycobacterium aviumintracellulare infection of patients with HIV. J Infect 1993; 26:55-66. https://doi.org/10.1016/0163-4453(93)96840-M
  26. Torriani FJ, McCutchan JA, Bozzette SA, Grafe MR, Havlir DV. Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J Infect Dis 1994;170: 1601-1605. https://doi.org/10.1093/infdis/170.6.1601
  27. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T. Incidence and natural history of Mycobacterium aviumcomplex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine: the Zidovudine Epidemiology Study Group.Am Rev Respir Dis 1992;146:285-289. https://doi.org/10.1164/ajrccm/146.2.285
  28. Shanson DC, Dryden MS. Comparison of methods for isolating Mycobacterium avium-intracellulare from blood of patients with AIDS. J Clin Pathol 1988;41:687-690. https://doi.org/10.1136/jcp.41.6.687
  29. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both: California Collaborative Treatment Group. N Engl J Med 1996;335:392-398. https://doi.org/10.1056/NEJM199608083350604
  30. Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 2000;30:749-756. https://doi.org/10.1086/313765
  31. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998;27: 1291-1294. https://doi.org/10.1086/515006
  32. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis: infectious Diseases Society of America. Clin Infect Dis 2000;30:662-678. https://doi.org/10.1086/313749
  33. Aberg JA, Powderly WG. Cryptococcosis. Adv Pharmacol 1997;37:215-251.
  34. Powderly WG, Cloud GA, Dismukes WE, Saag MS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994;18:789-792. https://doi.org/10.1093/clinids/18.5.789
  35. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis: the NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000;30:47-54. https://doi.org/10.1086/313603
  36. Van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome:National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337:15-21. https://doi.org/10.1056/NEJM199707033370103
  37. Luft BJ, Brooks RG, Conley FK, McCabe RE, Remington JS. Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. JAMA 1984;252:913-917. https://doi.org/10.1001/jama.1984.03350070031018
  38. Israelski DM, Chmiel JS, Poggensee L, Phair JP, Remington JS. Prevalence of Toxoplasma infection in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. J Acquir Immune Defic Syndr 1993;6:414-418.
  39. Kupfer MC, Zee CS, Colletti PM, Boswell WD, Rhodes R. MRI evaluation of AIDS-related encephalopathy: toxoplasmosis vs. lymphoma. Magn Reson Imaging 1990;8:51-57. https://doi.org/10.1016/0730-725X(90)90212-K
  40. Pierce MA, Johnson MD, Maciunas RJ, et al. Evaluating contrast-enhancing brain lesions in patients with AIDS by using positron emission tomography. Ann Intern Med 1995;123:594-598. https://doi.org/10.7326/0003-4819-123-8-199510150-00005
  41. Derouin F, Leport C, Pueyo S, et al. Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients: ANRS 005/ACTG 154 Trial Group. AIDS 1996;10:1521-1527. https://doi.org/10.1097/00002030-199611000-00010
  42. Katlama C, De Wit S, O'Doherty E, Van Glabeke M, Clumeck N. Pyrimethamine-clindamycin vs. pyrimethaminesulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22:268-275. https://doi.org/10.1093/clinids/22.2.268
  43. Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome: members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med 1993;329:995-1000. https://doi.org/10.1056/NEJM199309303291403
  44. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprimsulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992;117:106-111. https://doi.org/10.7326/0003-4819-117-2-106
  45. Arribas JR, Storch GA, Clifford DB, Tselis AC. Cytomegalovirus encephalitis. Ann Intern Med 1996;125:577-587. https://doi.org/10.7326/0003-4819-125-7-199610010-00008
  46. Dieterich DT, Rahmin M. Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acquir Immune Defic Syndr 1991;4(Suppl 1):S29-S35.
  47. Jabs DA, Van Natta ML, Kempen JH, et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 2002;133: 48-61. https://doi.org/10.1016/S0002-9394(01)01322-8
  48. Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. second eye involvement and retinal detachment. Ophthalmology 2004;111:2232-2239. https://doi.org/10.1016/j.ophtha.2004.05.028
  49. Holland GN. AIDS and ophthalmology: the first quarter century. Am J Ophthalmol 2008;145:397-408. https://doi.org/10.1016/j.ajo.2007.12.001
  50. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. visual outcomes: Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Ophthalmology 1994;101:1250-1261. https://doi.org/10.1016/S0161-6420(94)31181-X
  51. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. Treatment of cytomegalovirus retinitis with a sustainedrelease ganciclovir implant: the Ganciclovir Implant Study Group. N Engl J Med 1997;337:83-90. https://doi.org/10.1056/NEJM199707103370203
  52. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002;346:1119-1126. https://doi.org/10.1056/NEJMoa011759
  53. Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK, Tonascia JA. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol 2003;121:466-476. https://doi.org/10.1001/archopht.121.4.466
  54. Studies of Ocular Complications of AIDS Research Group the AIDS Clinical Trials Group. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Am J Ophthalmol 2001;131:457-467. https://doi.org/10.1016/S0002-9394(01)00840-6
  55. Weber T, Trebst C, Frye S, et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 1997;176: 250-254. https://doi.org/10.1086/514032
  56. Lang W, Miklossy J, Deruaz JP, et al. Neuropathology of the acquired immune deficiency syndrome (AIDS): a report of 135 consecutive autopsy cases from Switzerland. Acta Neuropathol 1989;77:379-390. https://doi.org/10.1007/BF00687372
  57. D'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004;55:320-328. https://doi.org/10.1002/ana.10827
  58. Casper C, Krantz E, Selke S, et al. Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J Infect Dis 2007;195: 30-36. https://doi.org/10.1086/509621
  59. The Korean Society for AIDS. Clinical guidelines for the treatment and prevention of opportunistic infections in HIV-infected Koreans. Infect Chemother 2012;44:93-139. https://doi.org/10.3947/ic.2012.44.3.93

Cited by

  1. 진행성 다발성 백질뇌병증을 합병한 HIV/AIDS 환자의 한양방 협진 치료 치험 1례 vol.38, pp.6, 2017, https://doi.org/10.22246/jikm.2017.38.6.1076